HK1201067A1 - Sialic acid analogs - Google Patents

Sialic acid analogs Download PDF

Info

Publication number
HK1201067A1
HK1201067A1 HK15101526.4A HK15101526A HK1201067A1 HK 1201067 A1 HK1201067 A1 HK 1201067A1 HK 15101526 A HK15101526 A HK 15101526A HK 1201067 A1 HK1201067 A1 HK 1201067A1
Authority
HK
Hong Kong
Prior art keywords
sialic acid
acid analogs
analogs
treatment
present
Prior art date
Application number
HK15101526.4A
Other languages
English (en)
Chinese (zh)
Inventor
埃米爾.卡吉斯
埃米尔.卡吉斯
史蒂文.賈格爾
史蒂文.贾格尔
何釗
何钊
Original Assignee
罕见病药物研发公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 罕见病药物研发公司 filed Critical 罕见病药物研发公司
Publication of HK1201067A1 publication Critical patent/HK1201067A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02Acyclic radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/10Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02Acyclic radicals
    • C07H7/027Keto-aldonic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
HK15101526.4A 2011-10-24 2012-10-24 Sialic acid analogs HK1201067A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550610P 2011-10-24 2011-10-24
US61/550,610 2011-10-24
PCT/US2012/061737 WO2013063149A1 (en) 2011-10-24 2012-10-24 Sialic acid analogs

Publications (1)

Publication Number Publication Date
HK1201067A1 true HK1201067A1 (en) 2015-08-21

Family

ID=48168447

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101526.4A HK1201067A1 (en) 2011-10-24 2012-10-24 Sialic acid analogs

Country Status (13)

Country Link
US (5) US8840926B2 (enExample)
EP (1) EP2771348B1 (enExample)
JP (1) JP6196224B2 (enExample)
KR (1) KR102049214B1 (enExample)
CN (1) CN103974965B (enExample)
AU (1) AU2012328874B2 (enExample)
BR (1) BR112014009760B1 (enExample)
CA (1) CA2849114C (enExample)
ES (1) ES2807890T3 (enExample)
HK (1) HK1201067A1 (enExample)
IL (1) IL231714B (enExample)
MX (1) MX347541B (enExample)
WO (1) WO2013063149A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241896B2 (en) 2008-12-19 2016-01-26 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
BR112013000776A2 (pt) 2010-07-13 2016-05-24 Ultragenyx Pharmaceutical Inc método e formulação para tratamento de deficiência de ácido siálico
KR102049214B1 (ko) 2011-10-24 2019-11-28 울트라제닉스 파마수티컬 인코포레이티드 시알산 유사체
KR20150000872A (ko) * 2012-01-18 2015-01-05 울트라제닉스 파마수티컬 인코포레이티드 시알산 결핍을 치료하기 위한 방법 및 제형
US10385085B2 (en) 2015-09-14 2019-08-20 Ultragenyx Pharmaceutical Inc. Crystal forms of sialic acid or salt or solvate thereof
CN121079430A (zh) * 2023-02-17 2025-12-05 奥特吉尼克斯制药公司 唾液酸衍生物的结晶形式及其使用方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6168418A (ja) 1984-09-11 1986-04-08 Kanto Ishi Pharma Co Ltd 去痰薬
JPS63139193A (ja) * 1986-11-28 1988-06-10 Mect Corp シアル酸誘導体1,7−ラクトン
US6156544A (en) 1993-06-09 2000-12-05 Glaxo Group Limited Process for the preparation of N-acetylneuraminic acid
CN1090022C (zh) 1995-04-04 2002-09-04 俄克拉荷马创伤治疗所 通过光动力疗法与免疫佐剂联合应用治疗癌症
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
CA2328085C (en) 1998-04-10 2006-08-22 Mitsubishi Chemical Corporation Solid dispersion containing sialic acid derivative
KR20030006721A (ko) 2001-07-14 2003-01-23 삼성전자 주식회사 리소그라피 시스템 및 이를 이용한 레티클 표면의 파티클제거방법
CN1671420A (zh) 2002-06-21 2005-09-21 诺和诺德医疗保健公司 Peg化因子ⅶ糖型
US7238677B2 (en) 2003-03-28 2007-07-03 Kimberly-Clark Worldwide, Inc. Prevention of urogenital infections
AU2004296404A1 (en) * 2003-12-09 2005-06-23 Spherics, Inc. Bioadhesive polymers with catechol functionality
JP2008535787A (ja) 2005-03-03 2008-09-04 マナテク・インコーポレーテツド 栄養補助剤の改変された放出のための方法及び組成物
EP2086515A2 (en) * 2006-03-02 2009-08-12 Vaunnex, Inc. Rate-controlled bioadhesive oral dosage formulations
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
CA2903133C (en) 2007-05-31 2021-10-19 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health N-acetyl mannosamine or derivatives thereof for use in treating a kidney disorder in a mammal
JP2010537997A (ja) 2007-08-27 2010-12-09 マサチューセッツ インスティテュート オブ テクノロジー 二機能性ポリマーに結合させたインフルエンザウイルス阻害剤
CN102316730A (zh) 2008-05-09 2012-01-11 天雅瑞药业有限公司 用于减轻全身性炎症和/或血管炎症的n-乙酰半胱氨酸(nac)的控释
KR101116864B1 (ko) 2008-08-01 2012-02-29 주식회사 베네비오 고지혈증, 지방간 또는 비만의 예방 또는 치료용 조성물
US20100160363A1 (en) 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
US9241896B2 (en) 2008-12-19 2016-01-26 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
US20100159001A1 (en) 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
KR20120023064A (ko) * 2009-05-15 2012-03-12 자이단호진 휴먼 사이언스 신코우자이단 Gne 단백질의 기능 저하에 기인하는 질환의 치료용 의약제, 식품 조성물 및 식품 첨가물
BR112013000776A2 (pt) 2010-07-13 2016-05-24 Ultragenyx Pharmaceutical Inc método e formulação para tratamento de deficiência de ácido siálico
KR102049214B1 (ko) 2011-10-24 2019-11-28 울트라제닉스 파마수티컬 인코포레이티드 시알산 유사체
KR20150000872A (ko) 2012-01-18 2015-01-05 울트라제닉스 파마수티컬 인코포레이티드 시알산 결핍을 치료하기 위한 방법 및 제형
ES2777838T3 (es) 2015-01-28 2020-08-06 Kyowa Hakko Bio Co Ltd Cristal de anhidrato de N-acetilneuraminato de amonio y procedimiento para producir el mismo
US10385085B2 (en) 2015-09-14 2019-08-20 Ultragenyx Pharmaceutical Inc. Crystal forms of sialic acid or salt or solvate thereof

Also Published As

Publication number Publication date
BR112014009760A2 (pt) 2017-04-18
US10065981B2 (en) 2018-09-04
EP2771348A4 (en) 2015-09-09
US20190127409A1 (en) 2019-05-02
CN103974965B (zh) 2019-09-24
IL231714A0 (en) 2014-05-28
EP2771348B1 (en) 2020-05-20
MX2014004928A (es) 2014-11-10
US20150038693A1 (en) 2015-02-05
CN103974965A (zh) 2014-08-06
AU2012328874A1 (en) 2014-04-10
BR112014009760A8 (pt) 2018-01-16
CA2849114C (en) 2020-12-15
EP2771348A1 (en) 2014-09-03
ES2807890T3 (es) 2021-02-24
US20200131215A1 (en) 2020-04-30
US9221858B2 (en) 2015-12-29
US10889607B2 (en) 2021-01-12
US10457701B2 (en) 2019-10-29
JP2014530882A (ja) 2014-11-20
KR20140084277A (ko) 2014-07-04
US20130122094A1 (en) 2013-05-16
AU2012328874B2 (en) 2017-08-31
MX347541B (es) 2017-04-28
WO2013063149A1 (en) 2013-05-02
BR112014009760B1 (pt) 2022-11-29
CA2849114A1 (en) 2013-05-02
IL231714B (en) 2018-10-31
US8840926B2 (en) 2014-09-23
US20160297846A1 (en) 2016-10-13
KR102049214B1 (ko) 2019-11-28
JP6196224B2 (ja) 2017-09-13

Similar Documents

Publication Publication Date Title
MD20150091A2 (ro) Compuşi antivirali
ZA201307793B (en) Novel compound useful for the treatment of degenerative and inflammatory diseases
ZA201404121B (en) Compositions for the treatment of dry eye
SMT201600464B (it) Procedimento per la preparazione di esterolo
AU2012213775A8 (en) 7-azaindole derivatives
IL231836A0 (en) The vehicle for treating the siege
ZA201404440B (en) Process for the preparation of travoprost
WO2012104823A3 (en) Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
SG10201900541QA (en) Derivatives of xanthone compounds
SG11201400939YA (en) Process for the preparation of methoxymelonal
PL2901857T3 (pl) Sposób wytwarzania 3-chloro-4,5,6-trifluoro-pikolinonitrylu
MX2013000009A (es) Procedimiento de preparacion de la sal de l-arginina de perindoprilo.
HK1201067A1 (en) Sialic acid analogs
GB201107985D0 (en) Process
IN2014DN03010A (enExample)
WO2012154879A3 (en) Autophagy inhibitors
EP2819995A4 (en) PROCESS FOR THE PREPARATION OF 3-METHYLSULFONYLPROPIONITRIL
MX2014002378A (es) Proceso para la preparacion de (r)-2-acetamido-n-bencil-3-metoxipr opionamida e intermediarios de la misma.
WO2014102759A3 (en) Process for the preparation of dasatinib and its intermediates
PL2581193T3 (pl) Sposób wytwarzania implantów lub produktów pośrednich takich implantów, jak również implanty i produkty pośrednie otrzymane tym sposobem
PT2593423E (pt) Processo para a preparação de agentes de contraste
PL2702045T3 (pl) Nowy sposób sporządzania Etrawiryny
EP2646424A4 (en) PROCESS FOR THE PREPARATION OF ENAMINES
WO2013064326A3 (de) Arjunolsäure zur erhöhung der sebumproduktion